Trastuzumab Offers Long-Term Survival Benefits in HER2+ Early Breast Cancer

Share this content:
Trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer is associated with superior long-term disease-free survival.
Trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer is associated with superior long-term disease-free survival.

SAN ANTONIO—Trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer is associated with superior long-term disease-free survival and overall survival rates, compared to observation, reported authors of a final 10-year follow up analysis from the phase 3 international HER (BIG 1-01) clinical trial. The findings were presented at the 2015 San Antonio Breast Cancer Symposium.1

“Results at completion of follow-up show sustained and stable DFS and OS benefit with trastuzumab,” reported lead study author Christian Jackisch, MD, PhD, of the Sana Klinikum Offenbach in Germany. “The standard of care remains 1 year of trastuzumab irrespective of hormone receptor [status].”

“No safety concerns or late cardiac safety signals emerged,” Dr Jackisch added.

Administration of the HER-2-receptor-targeting recombinant monoclonal antibody trastuzumab (T) concurrently or after adjuvant chemotherapy can prolong overall survival (OS) and disease-free survival (DFS) among women with HER2-positive (HER2+) early breast cancer (EBC).

“HERA (BIG 1-01) is an international, multicenter, phase 3 randomized trial involving 5102 women with HER2-positive EBC either nodal negative (tumor-size ≥ 1cm) or nodal positive,” Dr. Jackisch said. “After completion of primary therapy, including surgery, chemotherapy and radiotherapy as indicated, patients were randomly assigned to receive trastuzumab every 3 weeks for 1 year, or for 2 years, or to observation.”

RELATED: Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy

At a median followup of 11.0 years, survival benefits were found for trastuzumab (1- or 2-years) over those achieved in the observation cohort (trastuzumab 1-year vs observation: hazard ratio [HR] 0.74; 95% CI: 0.65-0.86; P < .0001).

There was no significant difference in survival between the trastuzumab 1- and 2-year study groups, however.

Reference

  1. Jackisch C, Piccart MJ, Gelber RD, et al. THERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis. Oral presentation at: San Antonio Breast Cancer Symposium 2015; December 10, 2015; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs